Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial 

This 2021 open label active-controlled clinical trial followed osteoarthritic patients for 6 weeks. The intervention group received low-dose curcumagalactomannosides (CGM) (400 mg once daily) in OA subjects. The treatment was compared with a standard combination of 500 mg glucosamine hydrochloride (GLN) and 415 mg chondroitin sulphate (CHN), supplied as a single oral dose twice a day. CGM exhibited  improvement in VAS, KPS and walking performance, respectively, compared to the baseline. 

References:

Thomas JV, Smina TP, Khanna A, Kunnumakkara AB, Maliakel B, Mohanan R, Krishnakumar IM. Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial. Phytother Res. 2021 Mar;35(3):1443-1455. doi: 10.1002/ptr.6907. Epub 2020 Nov 18. PMID: 33210408.